Uterine sarcoma: Clinicopathological characteristics, treatment and outcome in Iran

Asian Pacific Journal of Cancer Prevention

Volumn 9, Issue 3, 2008, Pages 421-426

  Ghaemmaghami, Fatemeh ^a   Zarchi, Mojgan Karimi ^b   Gilani, Mitra Modares ^a   Mousavi, Azamsadat ^a   Behtash, Nadereh ^a   Ghasemi, Mahsa ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chemotherapy; Iranian patients; Radiotherapy; Survival; Uterine sarcoma

Indexed keywords

EID: 67650866707     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bell SW, Kempson RL, Hendrickson MR (1994). Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol, 18, 535.
2. Benooit L, Arnold L, Cheynel N, et al (2005). The role of surgery and treatment trends in uterine sarcoma. EJSO, 31, 434-42
3. Bodner-Adler B, Bodner K, Obermair A, et al (2001). Prognostic parameters in carcinosarcomas of the uterus: a clinicopathologic study. Anticancer Res, 21, 3069-74.
4. Brooks SE, Zhan M, Cote T, Baquet CR (2004). Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol, 93, 204-8.
5. Chauveinc L, Deniaud C, Plancher X, et al (1999). Uterine sarcoma: the Curie Institute Experience. Prognosis factors and adjuvant treatments. Gynecol Oncol, 72, 232-7.
6. Curtin JP, Blessing JA, Soper JT, DeGeest K (2001). Paclitaxel in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol, 83, 268-70.
7. Dinh TA, Oliva EA, Fuller AF (2004). The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol, 92,648-52.
8. Ferrer F, Sabater S, Farrus B, et al (1999). Impact of radiotherapy on local control anf survival in uterine sarcomas: A retrospective study from the group oncologic catala-Occita. Int J Radiat Oncol Biol Phys, 44, 47-52.
9. Fujita H, Adachi S, Kigawa J, et al (2004). A clinicopathological study of uterine sarcoma in last decade-a retrospective study of KCOG/USSG inter group study. Adv Obstet Gynecol, 56
10. Gadducci A, Fabrini MG, Facchini V, et al (1989). Surgery and radiotherapy in the treatment of early stage uterine sarcomas. Eur J Gynaecol Oncol, 10, 276-80.
11. Gadduicci A, Romanini A (2001). Adjuvant chemotherapy in early stage. Uterine sarcomas: An open question. Eur J Gynecol Oncol, 22, 352-7.
12. Gerszten K, Faul C, Kounelis S, et al (1998). The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol, 68, 1-13.
13. Ghershenson DM, Kavanagh JJ, Copeland LJ, et al (1987). Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus. J Clin Oncol, 5, 618-21.
14. Giuntoli II RL, Metzinger DS, Dimarco CS et al(2003). Retrospective rewiew of 208 patients with lyomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol, 89, 460-9.
15. Hensly ML, Makir, Venkatarman E, et al (2002). Gemcitabin and docitaxel in patients with unresectable liomyosarcoma: Results of a phase II trial. J Clin Oncol, 20, 2824-31.
16. Hoffmann W, Schamandt S, Kortmann RD, et al (1996). Radiotherapy in the treatment of uterine sarcoma. A retrospective analysis of 54 cases. Gynecol Obstet Invest, 42, 49-57.
17. Hornback NB, Omura G, Major (1986). Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys, 12, 2127-30.
18. Iwasa Y, Haga H, Konishi I, et al (1998). Prognostic factors in uterine carcinosarcoma. Cancer, 82, 512-9.
19. Kelly K-L, Craighead PS (2005). Characteristics and management of uterine sarcoma patients treated at the Tom Baker Cancer Center. Int J Gynecol Cancer, 15, 132-9.
20. Knocke TH, Kucera H, Dorfle D, et al (1998). Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri. Cancer, 83, 1972-9.
21. Kokawa K, Nishiyama K, Ikeuchi M, et al (2006). Clinical outcomes of uterine sarcomas: results from 14 years worth of experience in the Kinki district in Japan (1990-2003). Int J Gynecol Cancer, 16, 1358-63.
22. Le T (2001). Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population. Eur J Surg Oncol, 27, 282-5.
23. Livi L, Andreopoulou E, Shah N (2004). Treatment of uterine sarcoma of the Royal Marsden hospital from 1974 to 1998. Clin Oncol, 16, 261-8.
24. Livi L, Paiar F, Shah N, et al (2003). Uterine sarcoma: Twentyseven years of experience. Int J Radiat Oncol Biol Phys, 57, 1366-73.
25. Major FJ, Blessing JA, Silverberg SG, et al(1993). Prognostic factors in early-stage uterine sarcoma: a Gynecologic Oncology Group study. Cancer, 71, 1702-9.
26. Meredith RF, Eisert DR, Kaka Z,et al (1986). An excess of uterine sarcoma after pelvic irradiation. Cancer, 58, 2003-7.
27. Moskovic E, MacSweeney E, Law M, et al (1993). Survival, patterns of spread and prognostic factors in uterine sarcoma: a study of 76 patients. Br J Radiol, 66, 1009-15.
28. Nola M, Babic D, Ilic J, et al (1996). Prognostic parameters for survival of patients with malignant mesenchymal tumours of the uterus. Cancer, 78, 2543-50.
29. Nordal R, Kristensen GB, Stenwig AE, et al (1997). An evaluation of prognostic factors in uterine carcinosarcoma. Gynecol Oncol, 67, 316-21
30. Olah S, Dunn JA, Gee H (1992). Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma. Br J Obstet Gynaecol, 99, 590-4.
31. Omura GA, Blessing JA, Major F, et al (1988). A randomized clinical trail of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol, 38, 233-9.
32. Pecorelli S (??). EORTC Gynecological cancer groups: adjuvant pelvic radiotherapy versus observation alone in patients with completely resected stage I or II high grade uterine sarcoma. JOURNAL DETAILS?
33. Platz CE, Benda JA (1995). Female genital tract cancer. Cancer, 75, 270.
34. Piver MS, Lele SB, Marchetti DL, et al (1998). Affect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas. J Surg Oncol, 38, 233-9.
35. Saga S, Yamashita K, Ishioka S, et al (2004). Preoperative diagnosis and treatment results in 106 patients uterine sarcoma in Hokkaido, Japan. Oncology, 67, 33-9.
36. Schwartz Z, Dgani R, Lancet M et al(1985). Uterine sarcoma in Israel: a study of 104 cases. Gynecol Oncol, 20, 354-63.
37. Spanos WJ, Taylor WJ, Gomez L, et al (1984). Malignant mixed Mullerian tumors of the uterus. Cancer, 53, 311-6.
38. Sutton G, Blessing JA, Malfetano JH (1996). Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol, 62, 226-9.
39. Sutton GP, Brunetto V, Kilgore L, et al (2000). A phase III trial of ifosmaide with without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol, 79, 147-53.
40. Wang CJ, Leung SW, Chen HC, et al (1998). The correlation of acute toxicity and late rectal injury in radiotherapy for cervical carcinoma: Evidence suggestive of consequentional late effect (CQLE). Int J Radiol Oncol Biol Phys, 40, 8.
41. Watanabe Y, Roy JN, Harrington PJ, et al (1998). Threedimensional lookup tables for Henschke applicator cervix treatment by HDR 192IR remote afterloading. Int J Radiat Oncol Biol Phys, 41, 1201-7.